VX 659/ivacaftor/tezacaftor - Vertex Pharmaceuticals

Drug Profile

VX 659/ivacaftor/tezacaftor - Vertex Pharmaceuticals

Alternative Names: Tezacaftor/VX-659/ivacaftor; VX-659/ivacaftor/VX-661; VX-659/TEZ/IVA; VX-659/VX-770/VX-661; VX659/ivacaftor/tezacaftor

Latest Information Update: 13 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Vertex Pharmaceuticals
  • Class Amides; Aminophenols; Antifibrotics; Cyclopropanes; Fluorobenzenes; Quinolones; Small molecules
  • Mechanism of Action Cystic fibrosis transmembrane conductance regulator stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Cystic fibrosis

Most Recent Events

  • 01 Mar 2018 Vertex Pharmaceuticals plans a phase III trial for Cystic Fibrosis (In children, In adolescents, In adults, In the elderly), in March 2018 (NCT03447249)
  • 01 Mar 2018 Vertex Pharmaceuticals announces intention to submit regulatory application for Cystic fibrosis (in patients with heterozygous for the F508del mutation and a minimal function mutation) in USA, Europe and other regions
  • 01 Mar 2018 Vertex Pharmaceuticals announces intention to submit regulatory application for Cystic fibrosis (in patients with two F508del mutations) in USA, Europe and other regions
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top